Related Experiment Videos
[Magnesium therapy in acute myocardial infarction. New points of view]
1Institutt for farmakoterapi, Oslo.
Insights
Early magnesium infusion may reduce mortality in acute myocardial infarction patients. Timing and dosage are critical factors influencing magnesium
Area of Science:
- Cardiology
- Pharmacology
Background:
- Intravenous magnesium has shown potential benefits in smaller trials for acute myocardial infarction (AMI).
- Conflicting results exist, with larger trials like ISIS-4 showing no benefit.
Purpose of the Study:
- To investigate the discrepancies in magnesium's efficacy for AMI.
- To determine the optimal timing and dosage of magnesium administration in AMI.
Main Methods:
- Review of placebo-controlled, randomized studies including LIMIT-2 and ISIS-4.
- Analysis of patient characteristics, timing of magnesium infusion, and reperfusion status.
Main Results:
- LIMIT-2 suggested magnesium reduced mortality when given early, before reperfusion.
- ISIS-4 found no benefit, possibly due to later administration post-reperfusion and higher initial dose.
Conclusions:
- Early magnesium infusion is a safe, simple, and cost-effective addition to standard AMI therapy.
- Timing of magnesium administration relative to reperfusion is crucial for efficacy.
- Further research may clarify optimal dosing and patient selection for magnesium therapy in AMI.
Abstract:
In some smaller placebo-controlled, randomized studies, and in one larger such study (LIMIT-2, 2,136 patients), intravenous infusion of magnesium was shown to reduce early and late mortality of ischaemic heart disease in patients admitted with suspected acute myocardial infarction. In contrast, the ISIS-4 trial, which included 58,050 patients, did not show any benefit from magnesium. These discrepancies may be explained as follows; In LIMIT-2, magnesium was given early and before spontaneous or therapeutic thrombolysis (36% of the patients), in ISIS-4, however, the patients were likely to have undergone myocardial reperfusion in response to thrombolysis (70% of the patients) before receiving magnesium. Myocardial stunning may develop in association with reperfusion. Magnesium given before and during ischaemia attenuates postischaemic myocardial dysfunction. The absence of effect of magnesium in ISIS-4 is also thought to be related to the higher dose administered during the first 24 hours in this study. Early infusion of magnesium in acute myocardial infarction is a useful addition to standard therapy, and is simple, cheap and safe to administer.